Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular...
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular...
Lineage Cell Therapeutics的股價上漲，此前該公司公佈了參加針對繼發於年齡相關性黃斑的地理萎縮患者 RG6501 的1/2a期臨床研究的患者的24個月視力結果...
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration.
Lineage Cell Therapeutics公佈了針對繼發於年齡相關性黃斑變性的地理萎縮患者 RG6501 的1/2a期臨床研究的患者的24個月視力結果，此後，Lineage Cell Therapeutics的股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。